close

Agreements

Date: 2011-04-27

Type of information: Collaboration agreement

Compound: AT001/r84

Company: Affitech (Denmark) University of Texas Southwestern Medical Center (USA)

Therapeutic area:

Type agreement:

Collaboration

Action mechanism:

anti-VEGF antibody

Disease:

Details:

Affitech has signed a sponsored research agreement with Dr. Rolf Brekken at the University of Texas Southwestern Medical Center to further understand the mechanism and potential differentiation of Affitech’s lead antibody drug candidate AT001/r84. The university already has an existing relationship with Affitech. It has previously studied AT001/r84 in mouse models and will now conduct comparative studies with bevacizumab in animal models. Affitech will obtain certain rights to intellectual property developed during the course of the research with a view to profitable commercialization of such intellectual property for Affitech’s benefit. The university will perform the research and grant certain rights to such intellectual property.

Financial terms:

Latest news:

Is general: Yes